Found
Personalized weight care spanning medication, behavior, and biology
Founded 2019 · Austin, TX · Private · Website
Our verdict
The default recommendation for a self-insured employer buying full-service clinical care. Push hard on contract term and get the step-therapy criteria into the agreement itself.
Scorecard
How it scored
Scored against the published rubric. Weights are fixed before review and identical for every vendor.
Prescriber credentials, titration protocol, comorbidity screening, and off-ramp planning.
Quality of published results: peer review, sample size, control group, and follow-up duration.
Ability to hold net pharmacy spend down: gating, biosimilar strategy, and risk sharing.
Eligibility-level reporting, claims feeds, and whether you can audit the vendor's own numbers.
PBM, carrier, HRIS, and point-solution interoperability without custom engineering.
Time to first appointment, app quality, care-team continuity, and support responsiveness.
Analysis
What we found
Found is the most balanced full-service option in this evaluation. It prescribes, which means it can act on cost, and it is the only clinical vendor here that treats step therapy as a core protocol rather than a concession. The formulary breadth matters more than it sounds: a large share of members respond adequately to substantially cheaper agents, and Found's model is built to find them rather than route everyone to the highest-cost branded option. Evidence is real but younger than the market leaders.
Strengths
- Step therapy is built into the clinical protocol rather than bolted on by your PBM, which is unusual and genuinely valuable
- Broadest medication formulary in this set, so members who do not need a GLP-1 do not get one by default
- Member experience scores near the top of the category without the premium price of the boutique clinical vendors
Limitations
- Outcomes evidence, while peer-reviewed, has short follow-up relative to Omada or Virta
- Outcome guarantees are only available at scale, which puts them out of reach for most mid-market buyers
- 24-month term with 90-day notice makes a genuine pilot difficult to structure
Best for
Self-insured employers who want prescribing under their roof but need a credible answer to 'how do you keep people off the expensive drug?'
Watch out
Step therapy is a clinical default, not a contractual commitment. Get the escalation criteria written into the agreement.
The details
Commercial and clinical specifics
The facts you will need to build a comparison grid. Verify each against the vendor's own documentation before contracting.
Pricing
- Model
- PMPM on enrolled members with tiered engagement pricing
- PMPM range
- $45–$85
- Setup fee
- None below 10,000 lives
- Medications included
- No
- Performance guarantees
- Engagement guarantee standard; outcomes guarantee negotiable above 5,000 lives
Contract
- Minimum lives
- 500
- Term
- 24 months
- Termination notice
- 90 days
Eligibility
- BMI threshold
- BMI ≥ 27
- Prior authorization
- Yes
- Step therapy
- Yes
- Comorbidity required
- No
Clinical model
- Prescribes
- Yes
- Care team
- Physicians, Nurse practitioners, Registered dietitians, Behavioral coaches
- Titration protocol
- Protocolized titration with step therapy through lower-cost agents before branded GLP-1s
- Off-ramp
- Maintenance track with scheduled dose-reduction trials
- Formulary
- Semaglutide, Tirzepatide, Bupropion/naltrexone, Metformin, Phentermine
Outcomes evidence
- Headline claim
- Roughly 8% average weight loss at 12 months among members with 12-month weight data, in a peer-reviewed analysis of 66,000 members
- Evidence level
- Peer-reviewed observationalPublished cohort data, no randomization.
- Sample size
- 66,000 members analysed; about 9,000 with 12-month weight data
- Follow-up
- 12 months, with longer-term follow-up published separately
Sources
- Long-term weight loss outcomes in a virtual weight care clinic (PMC)Peer-reviewed real-world analysis of Found members
- Found announces peer-reviewed weight loss resultsCompany announcement of the 66,000-member analysis
Outcomes verified 2026-09-19. Pricing and contract figures on this page are category planning benchmarks, not vendor quotes — see methodology.
Integrations
- PBMs
- CVS Caremark, Express Scripts, Optum Rx
- Carriers
- Aetna, Cigna, UnitedHealthcare
- HRIS
- Workday, ADP, UKG, Paycom
- Eligibility file
- 834 or flat file, weekly cadence
Formulary
Found by medication
How a vendor positions each molecule reveals more about its cost discipline than any single score. First-line means an eligible member can start immediately; escalation means a documented lower-cost trial comes first.
Found Reviews Semaglutide
GLP-1 receptor agonist
Reached only after a documented trial of lower-cost therapy. Step therapy is written into Found's clinical protocol rather than bolted on by your PBM, which is unusual among prescribing vendors.
Found Reviews Tirzepatide
Dual GIP/GLP-1 receptor agonist
Sits at the top of the escalation ladder. Members generally reach it only after both a lower-cost agent and, in many cases, semaglutide have been tried.
Found Reviews Metformin
Biguanide
The default first rung. Found's economics improve when members respond here and never escalate, which is the alignment self-insured buyers should be looking for.
Alternatives
Others in full-service clinical
Same category, so these are genuine substitutes rather than different products at different prices.
Board-certified obesity medicine delivered virtually
- PMPM benchmark
- $58–$105
- Minimum lives
- 500
Combined cardiometabolic and mental health care in one care team
- PMPM benchmark
- $38–$78
- Minimum lives
- 1,000
Metabolic reset combining prescribing with intensive one-to-one coaching
- PMPM benchmark
- $65–$110
- Minimum lives
- 500